Bio

At Prescient, I am responsible for advancing the development of a next generation Chimeric Antigen Receptor T and or NK Cell therapy technology, called OmniCAR, along with small molecule targeted therapies. OmniCAR is re-defining CAR-Immune cell therapies by enabling CAR Activation and Tumor cell killing in a dose-dependent fashion, turning on/off immune cell activity without killing the CAR cells, re-directing CAR cells to new antigen targets in-situ, and/or co-arming two or more antigen targets simultaneously. Prior to Prescient, he was Director of Global Business Development and Strategic Partnerships for the Global non-profit organization PATH (www.path.org) where he was involved in the identification of new and innovative partnerships for vaccine and therapeutics development applicable to low and middle income countries. A BD and Licensing Leader with outstanding relationship building, clinical asset and technology evaluation, innovation, commercialization, and deal closing experience. Deep understanding of biologics clinical pathway and experience with regulatory submissions to phase I trial management. Clinical asset prospecting, due diligence, agreements, valuation (rNPV), licensing, acquisitions, market analysis and alliance management of vaccines, advanced therapeutics (cell and gene therapies), and traditional biologics. At Albumedix, I was responsible for asset in-licensing, alliances, and out-licensing, search/evaluation of clinical assets and strategic review. I led initiatives around the applications of our core technologies in stem cell therapy, gene therapy, and vaccines. At Meridian, I was responsible for biologics manufacturing leads, proposal writing, and contract negotiations. I negotiated global exclusive license for the Parvovirus B19 vaccine from NIH and was instrumental in the manufacture, IND approval, and Phase I study of this vaccine. I led development and commercialization of the RSV Memphis 37 clinical challenge virus used in over 6 human trials. I am also currently an adjunct professor in the Master’s in Clinical Drug Development program at the UC College of Pharmacy (now > 12 yrs). I teach Biologics Discovery and Biotech Business Management. I was awarded the prestigious “Outstanding Adjunct Faculty Award” for vital contributions to the University Teaching mission for 2018-2019. As a postdoc I received the APS Fellowship in Physiological Genomics (only 2 given annually) and a NIH NRSA. Specialties: Biopharmaceuticals, protein therapeutics, vaccines, gene therapy, cell therapy, oncology, and immunomodulation.